<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Recent reports have documented the development of renal <z:e sem="disease" ids="C0034155" disease_type="Disease or Syndrome" abbrv="">thrombotic microangiopathy</z:e> in patients with <z:hpo ids='HP_0011010'>chronic</z:hpo> myeloid <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:mp ids='MP_0005481'>CML</z:mp>) who have undergone treatment with interferon-alpha </plain></SENT>
<SENT sid="1" pm="."><plain>The pathogenesis of the renal lesion in such cases remains unclear </plain></SENT>
<SENT sid="2" pm="."><plain>We report the case of a patient with <z:hpo ids='HP_0011010'>chronic</z:hpo> myeloid <z:hpo ids='HP_0001909'>leukemia</z:hpo> who developed <z:hpo ids='HP_0000083'>renal failure</z:hpo> and <z:hpo ids='HP_0000100'>nephrotic syndrome</z:hpo> while being treated with <z:chebi fb="0" ids="44423">hydroxyurea</z:chebi> and interferon-alpha </plain></SENT>
<SENT sid="3" pm="."><plain>The renal biopsy showed features of <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C0034155" disease_type="Disease or Syndrome" abbrv="">thrombotic microangiopathy</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>The patient had serologic and functional evidence of anti-<z:chebi fb="0" ids="16247">phospholipid</z:chebi> antibody </plain></SENT>
<SENT sid="5" pm="."><plain>Interferon-alpha is known to cause induction of multiple autoantibodies </plain></SENT>
<SENT sid="6" pm="."><plain>We propose that in the context of <z:mp ids='MP_0005481'>CML</z:mp>, interferon-alpha treatment can induce pathogenic anti-<z:chebi fb="0" ids="16247">phospholipid</z:chebi> antibodies that result in renal <z:e sem="disease" ids="C0034155" disease_type="Disease or Syndrome" abbrv="">thrombotic microangiopathy</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>This has important implications for patients with <z:mp ids='MP_0005481'>CML</z:mp> receiving immune-stimulating therapy because it suggests that prospective monitoring of such patients for anti-<z:chebi fb="0" ids="16247">phospholipid</z:chebi> antibody might identify those at risk of developing <z:e sem="disease" ids="C0034155" disease_type="Disease or Syndrome" abbrv="">thrombotic microangiopathy</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>Furthermore, patients with established anti-<z:chebi fb="0" ids="16247">phospholipid</z:chebi> antibody syndrome in this context might benefit from intervention such as early anticoagulation </plain></SENT>
</text></document>